Ajinomoto Bio-Pharma Services Wins "Best ADC Preclinical Publication 2024" Award for AJICAP® Technology at 2025 World ADC Awards
Recognition underscores Ajinomoto Bio-Pharma Services' innovation and scientific excellence in advancing next-generation antibody-drug conjugate technologies TOKYO, Nov. 17, 2025 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a...
Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.
AJICAP® Antibody-Drug Conjugate Manufacturing Technology Contributes to Enhanced Efficacy of Antibody Drugs TOKYO, May 7, 2025 /PRNewswire/ -- Ajinomoto Co., Inc. (President: Shigeo Nakamura, Headquarters: Chuo-ku, Tokyo, hereinafter referred to as...